Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 03, 2024 16:30 ET
|
Fate Therapeutics, Inc.
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and...
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 22, 2024 16:30 ET
|
Fate Therapeutics, Inc.
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed /...
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024 08:44 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 01, 2024 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024 16:01 ET
|
Fate Therapeutics, Inc.
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...